NT_1170x120_1-11-18

McKesson Specialty Health

McKesson to buy RxCrossroads from CVS for $735 million

McKesson to buy RxCrossroads from CVS for $735 million

SAN FRANCISCO — McKesson Corp. announced late Monday that it had signed a definitive agreement to purchase RxCrossroads, a provider of tailored services to pharmaceutical and biotechnology manufacturers, from CVS Health. The transaction is valued at $735 million, or approximately $635 million net of the present value ofincremental cash tax benefits, and will be funded by